ライフサイエンスコーパス: tear fluid

1 d its impact on nanoparticle behavior in the tear fluid.

2 al of 174 proteins that were detected in the tear fluid.

3 hydrodynamic diameter after interacting with tear fluid.

4 conduct the first O-glycoproteomic study of tear fluid.

5 nds regulate the production and secretion of tear fluid.

6 9 activity assay in 1 microL of unstimulated tear fluid.

7 n composition and amount of O-glycans in the tear fluid.

8 icrobial peptides have been described in the tear fluid.

9 bead assay were used to quantify IL-1beta in tear fluid.

10 lm is also dictated by the amount of aqueous tear fluid.

11 ction between the lipid film and the aqueous tear fluid.

12 biologically inactive precursor IL-1 beta in tear fluid.

13 ace of the human eye and is present in human tear fluid.

14 human corneal epithelium and are present in tear fluid.

15 ase B (92 kDa) activity (P < 0.001) in their tear fluid.

16 ymphocytes, and increased bioavailability in tear fluids.

17 ntrations in rosacea-affected than in normal tear fluids.

18 the average glucose concentrations found in tear fluid (0.15 mM).

19 sed by fluorometric measurement of collected tear fluid 15 minutes after instillation of 1% sodium fl

20 tective than tear fluid (80% protection with tear fluid, 48% with sulfacetamide).

21 t of tear fluid was less cytoprotective than tear fluid (80% protection with tear fluid, 48% with sul

22 When nanoparticles are introduced into the tear fluid, a layer of protein corona is formed on their

23 neal surface caused by trapping bacteria and tear fluid against the cornea under the lens.

24 Nuclease deficiency in tear fluid allows eDNA and NETs to accumulate in precorn

25 on in both tear fluid and sulfacetamide, but tear fluid also blocked bacterial swimming motility.

26 Tear fluid also significantly reduced the severity of in

27 th as the source of the aqueous component of tear fluid and as the site of autoimmune pathology in th

28 s cytokines in cultured CECs, its absence in tear fluid and CIC samples suggests that IL-1beta does n

29 y revealed bacterial chain formation in both tear fluid and sulfacetamide, but tear fluid also blocke

30 factant protein D (SP-D) is present in human tear fluid and that it can protect corneal epithelial ce

31 Tear fluid and the corneal epithelium combine to make a

32 pressed in the lacrimal gland, secreted into tear fluid, and detected only in primates.

33 rstanding of the interplay between bacteria, tear fluid, and the corneal epithelium that determines h

34 peptides that are likely to be components of tear fluid are expressed by acinar cells and show pronou

35 xpression pattern of inflammatory markers in tear fluids at baseline might serve as a prognostic fact

36 These cytokines were also measured in normal tear fluid before and after nasal stimulation to induce

37 Tear fluid biomarker analysis and new imaging technology

38 opathy screening based on the examination of tear fluid biomarker changes.

39 e assumed to contribute to the production of tear fluid, but little is known about their function.

40 These data show that human tear fluid can protect against P. aeruginosa corneal inf

41 We tested the hypothesis that whole human tear fluid can protect corneal epithelia against P. aeru

42 These results suggest that human tear fluid can protect corneal epithelial cells against

43 Viable counts were performed on tear fluid collected at time points ranging from 3 to 14

44 RER1, ACTB, GAPDH, PGK1, UBC, and AP3D1) in tear fluid collected from individuals with dry eye disea

45 ic, five invasive)/ml with or without reflex tear fluid collected from the conjunctival sacs of human

46 e was evaluated by measuring fluorescence in tear fluid collected from the inferior meniscus 15 minut

47 Tear fluid collected using Schirmer's strip was used to

48 Immediately after tear fluid collection, conjunctival epithelium was obtai

49 1 inflammatory markers was observed in DAOSD tear fluids compared to baseline in AD patients.

50 Tear fluid comprises a diverse group of extracellular gl

51 s correlated with delayed tear clearance and tear fluid concentration of interleukin-1alpha, a proinf

52 We previously reported that human tear fluid could protect individual human corneal epithe

53 chia coli-induced travelers' diarrhea and in tear fluid derived from virally associated corneal disea

54 ion, even when inoculated ex vivo to exclude tear fluid effects.

55 tions between gold nanoaprticles (AuNPs) and tear fluid, focusing on the physicochemical changes of t

56 eloped in this study that extracted 10 uL of tear fluid from a tear Schirmer strip.

57 work for future biochemical investigation of tear fluid glycoproteins and their application as diagno

58 e most comprehensive characterization of the tear fluid glycoproteome to date, elucidating the glycos

59 Within the tear fluid glycoproteome, lacritin is highly expressed a

60 sity of corneal fluorescein staining and the tear fluid IL-1 alpha concentration (r(2) = 0.17, P < 0.

61 Significantly higher levels of tear fluid IL-1B, IL-6, LIF, IL-17A, TNFa, IFNa/B/y, EPO

62 Tear fluid IL-1beta and MMP-9 concentrations and the exp

63 omoter polymorphisms and TNF-alpha levels in tear fluid in scarring trachoma, a large matched-pair ca

64 sent study, we examined the effects of human tear fluid in vivo.

65 a, precursor IL-1 beta, and IL-1Ra in reflex tear fluid, indicating that the lacrimal glands may secr

66 The tear fluid is a readily accessible, potential source for

67 WB assay, assessment of lactoferrin in human tear fluid is demonstrated with a goal of advancing towa

68 Tear fluid levels of the inflammatory markers IL-1beta,

69 systemic disease scores that correlated with tear fluid loss and eyelid edema.

70 Boiled tear fluid lost bacteriostatic activity and effects on b

71 The tear fluid MMP-9 concentration increased in response to

72 Tear fluid N-Glycome from patients affected with vernal

73 Tear fluid nuclease activity was decreased significantly

74 amount of ocular surface eDNA and evaluated tear fluid nuclease activity.

75 ivity was evaluated by gelatin zymography in tear fluid obtained from 13 patients with ocular rosacea

76 IL-1 beta, was significantly elevated in the tear fluid of both dry-eye groups compared with normal s

77 els of IL-1beta protein were detected in the tear fluid of both groups.

78 mined whether nucleases are deficient in the tear fluid of dry eye disease (DED) patients, and whethe

79 se (MMP)-9 activity has been observed in the tear fluid of dry eye patients.

80 f the increased concentration of IL-1 in the tear fluid of patients with dry-eye disease.

81 MMP-3 was detected exclusively in the tear fluid of patients with ocular rosacea who had corne

82 The tear fluid of patients with Sjogren syndrome has reduced

83 cin MUC5AC were significantly reduced in the tear fluid of patients with Sjogren syndrome, corroborat

84 r concentration of pro-MMP-9 (92 kDa) in the tear fluid of rosacea patients than controls.

85 d levels of anti-MBP immunoglobulin A in the tear fluid of the immunized animals.

86 med at investigating inflammatory markers in tear fluids of patients on dupilumab therapy.

87 inoculation was performed ex vivo to exclude tear fluid or corneas were pretreated with EGTA to disru

88 he extracellular domain is released into the tear fluid or culture media.

89 r surface epithelia but is also found in the tear fluid, presumably in a soluble form, as found on th

90 ctrometry (MS) was performed to quantify the tear fluid proteins from chronic SJS/TEN patients (n = 2

91 A total of 1692 tear fluid proteins were identified, of which 470 were s

92 icines and their route of administration via tear fluid remain poorly understood.

93 However, the tear fluid remains largely unexplored as a biomarker sou

94 Tear fluid retarded growth of only 50% of the P. aerugin

95 alomucin complex was immunoprecipitated from tear fluid samples and both corneal and conjunctival epi

96 ntagonist (IL-1Ra) were measured by ELISA in tear fluid samples obtained from normal individuals and

97 Conjunctival impression cytology and tear fluid samples were collected at baseline and after

98 nM, which when delivered topically increased tear fluid secretion in mice and showed efficacy in an e

99 In vivo pharmacokinetic studies in rabbit tear fluid showed significant increase in mean residence

100 In vitro, human tear fluid significantly reduced the ability of invasive

101 0.15 mM glucose concentrations in artificial tear fluid solution.

102 evealed that purified elastase could degrade tear fluid SP-D in vivo.

103 tion of RNA and gene expression changes from tear fluid that could be used to monitor or study eye di

104 Dilution of tear fluid threefold significantly reduced cytoprotectio

105 of rigorous validation in studies involving tear fluid to ensure accurate gene expression results, t

106 c channel in contact lens sensors allows for tear fluid to flow through the sensing region, enabling

107 Factors in tear fluid trigger keratocyte loss after removal of the

108 Tear fluid was collected at day 0 and day 7 visits, and

109 Unstimulated tear fluid was collected from patients with ocular rosac

110 Human tear fluid was collected from the inferior conjunctival

111 Tear fluid was collected from the inferior fornix of nor

112 Tear fluid was found to reduce the severity of disease w

113 on of IL-1 alpha and mature IL-1 beta in the tear fluid was increased, and the concentration of precu

114 ith bacteriostatic activity matching that of tear fluid was less cytoprotective than tear fluid (80%

115 Without perturbing the eyeball, 3 microL of tear fluid was sampled from the marginal conjunctiva und

116 concentrations of IL-1beta and TNF-alpha in tear fluid washings and in corneal and conjunctival epit

117 the concentrations of IL-1beta and MMP-9 in tear fluid washings and the concentrations of IL-1beta a

118 se (MMP)-9 concentration and activity in the tear fluid were evaluated with gelatin zymography and wi

119 human corneal epithelial cultures and human tear fluid were incubated with MMP-3.

120 ro-MMP-9 and IL-1alpha concentrations in the tear fluid were measured by enzyme-linked immunosorbent

121 Tear fluids were analyzed by microsphere-based immunoass

122 Tear fluids were collected from AD patients with DAOSD (

123 hich showed marked upregulation in patients' tear fluid when normalized with the top-rated reference

124 Treatment of the supernatant and tear fluid with MMP-3 resulted in two bands with molecul

125 f corneal sizes and then quickly dissolve in tear fluid within a minute, enabling an initial burst re

126 e then inserted into the volume of collected tear fluids within the capillaries for detection.